Brief: Theranexus Announces Inclusion Of First Patient In Phase 2 Clinical Trial For THN102

Thx Pharma SA

16/07/2018 17:14

July 16 (Reuters) - THERANEXUS SA  ALTHX.PA :
    * ANNOUNCES THE INCLUSION OF THE FIRST PATIENT IN ITS PHASE 2 CLINICAL TRIAL EVALUATING ITS
DRUG
CANDIDATE THN102 IN EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS WITH PARKINSON'S DISEASE
    * RESULTS OF THE STUDY EXPECTED IN MID 2019
    * SAYS THE STUDY WILL BE CONDUCTED IN MORE THAN 20 CENTRES IN EUROPE AND THE UNITED STATES
    * SAYS THE PRIMARY ENDPOINT OF THE STUDY IS TREATMENT TOLERANCE OF THE DRUG CANDIDATE THN102
IN
THESE PATIENTS,
    * WITH SECONDARY EFFICACY ENDPOINTS INCLUDING AN EVALUATION OF SLEEPINESS, VIGILANCE AND
COGNITION.

Source text: https://bit.ly/2NTCGC8
Further company coverage:  ALTHX.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))